Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cells

Masuda,Kenta; Banno,Kouji; Yanokura,Megumi; Tsuji,Kosuke; Kobayashi,Yusuke; Kisu,Iori; Ueki,Arisa; Yamagami,Wataru; Nomura,Hiroyuki; Tominaga,Eiichiro; Susumu,Nobuyuki; Aoki,Daisuke

doi:10.3892/or.2012.1912

Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cells

Authors:
- Kenta Masuda
- Kouji Banno
- Megumi Yanokura
- Kosuke Tsuji
- Yusuke Kobayashi
- Iori Kisu
- Arisa Ueki
- Wataru Yamagami
- Hiroyuki Nomura
- Eiichiro Tominaga
- Nobuyuki Susumu
- Daisuke Aoki
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, Japan
Published online on: July 13, 2012 https://doi.org/10.3892/or.2012.1912
Pages: 1146-1152
Copyright: © Masuda et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The Werner (WRN) gene codes for a DNA helicase that contributes to genomic stability and has been identified as the gene responsible for progeria. Recent studies have shown reduced WRN expression due to aberrant DNA hypermethylation in cancer cells. Furthermore, WRN expression is thought to affect sensitivity to DNA topoisomerase I inhibitors in cancer therapy. In this study, we examined the relationship between aberrant DNA hypermethylation of WRN and the sensitivity of cervical cancer cells to anticancer drugs. DNA was extracted from samples from 22 patients with primary cervical cancer and 6 human cervical cancer-derived cell lines. Aberrant DNA hypermethylation was analyzed by methylation-specific PCR. WRN expression in cultured cells before and after addition of 5-aza-2-deoxycytidine, a demethylating agent, was examined using RT-PCR. The sensitivity of cells to anticancer drugs was determined using a collagen gel droplet embedded culture drug sensitivity test (CD-DST). siRNA against WRN was transfected into a cervical cancer-derived cell line with high WRN expression. Changes in drug sensitivity after silencing WRN were determined by CD-DST. Aberrant DNA hypermethylation and decreased expression of WRN were detected in 7/21 cases of primary cervical cancer and in two cervical cancer-derived cell lines. These two cell lines showed high sensitivity to CPT-11, a topoisomerase I inhibitor, but became resistant to CPT-11 after treatment with 5-aza-2-deoxycytidine. Transfection of siRNA against WRN increased the sensitivity of the cells to CPT-11. Aberrant DNA hypermethylation of WRN also increased the sensitivity of cervical cancer cells to CPT-11. Therefore, epigenetic inactivation of this gene may be a biomarker for selection of drugs for the treatment of cervical cancer. This is the first report to show a relationship between the methylation of the WRN gene and sensitivity to CPT-11 in gynecological cancers.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer Statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2	Forouzanfar MH, Foreman KJ, Delossantos AM, et al: Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 378:1461–1484. 2011. View Article : Google Scholar : PubMed/NCBI
3	zur Hausen H: Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res. 49:4677–4681. 1989.PubMed/NCBI
4	Munoz N, Bosch FX, de Sanjosé S, et al: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 348:518–527. 2003. View Article : Google Scholar : PubMed/NCBI
5	zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2:342–350. 2002.PubMed/NCBI
6	Jones PA and Laird PW: Cancer epigenetics comes of age. Nat Genet. 21:163–167. 1999. View Article : Google Scholar : PubMed/NCBI
7	Baylin SB and Herman JG: DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16:168–174. 2000. View Article : Google Scholar : PubMed/NCBI
8	Esteller M: Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet. 16:50–59. 2007. View Article : Google Scholar
9	Virmani AK, Muller C, Rathi A, Zoechbauer-Mueller S, Mathis M and Gazdar AF: Aberrant methylation during cervical carcinogenesis. Clin Cancer Res. 7:584–589. 2001.PubMed/NCBI
10	Wong Y, Chung TK, Cheung T, et al: Methylation of p16^INK4A in primary gynecologic malignancy. Cancer Lett. 136:231–235. 1999.PubMed/NCBI
11	Dong SM, Kim H-S, Rha S-H and Sidransky D: Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res. 7:1982–1986. 2001.PubMed/NCBI
12	Kuzmin I, Liu L, Dammann R, et al: Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection. Cancer Res. 63:1888–1893. 2003.PubMed/NCBI
13	Agrelo R, Cheng W-H, Setien F, et al: Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci USA. 103:8822–8827. 2006. View Article : Google Scholar : PubMed/NCBI
14	Yu CE, Oshima J, Wijsman EM, et al: Mutations in the consensus helicase domains of the Werner syndrome gene. Werner’s Syndrome Collaborative Group. Am J Hum Genet. 60:330–341. 1997.PubMed/NCBI
15	Muftuoglu M, Oshima J, Kobbe C, Cheng W-H, Leistritz DF and Bohr VA: The clinical characteristics of Werner syndrome: molecular and biochemical diagnosis. Hum Genet. 124:369–377. 2008. View Article : Google Scholar : PubMed/NCBI
16	Goto M, Miller RW, Ishikawa Y and Sugano H: Excess of rare cancers in Werner syndrome (adult progeria). Cancer Epidemiol Biomarkers Prev. 5:239–246. 1996.PubMed/NCBI
17	Epstein CJ, Martin GM, Schultz AL and Motulsky AG: Werner’s syndrome a review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process. Medicine. 45:177–221. 1966.
18	Huang S, Lee L, Hanson NB, et al: The spectrum of WRN mutations in Werner syndrome patients. Hum Mutat. 27:558–567. 2006. View Article : Google Scholar
19	Shaheen AC, Malcolm CC, Neil RJC, et al: Two novel regions of interstitial deletion on chromosome 8p in colorectal cancer. Oncogene. 18:657–665. 1999. View Article : Google Scholar : PubMed/NCBI
20	Armes JE, Hammet F, de Silva M, et al: Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers. Oncogene. 23:5697–5702. 2004. View Article : Google Scholar : PubMed/NCBI
21	Futami K, Takagi M, Shimamoto A, Sugimoto M and Furuichi Y: Increased chemotherapeutic activity of camptothecin in cancer cells by siRNA-induced silencing of WRN helicase. Biol Pharm Bull. 30:1958–1961. 2007. View Article : Google Scholar : PubMed/NCBI
22	Hsiang YH, Hertzberg R, Hecht S and Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 260:14873–14878. 1985.PubMed/NCBI
23	Hsiang YH, Lihou MG and Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:5077–5082. 1989.
24	Thigpen T: The role of chemotherapy in the management of carcinoma of the cervix. Cancer J. 9:425–432. 2003. View Article : Google Scholar : PubMed/NCBI
25	Takeuchi S, Dobashi K, Fujimoto S, et al: A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers. Gan To Kagaku Ryoho. 18:1681–1689. 1991.(In Japanese).
26	Susumu N, Aoki D, Noda T, et al: Diagnostic clinical application of two-color fluorescence in situ hybridization that detects chromosome 1 and 17 alterations to direct touch smear and liquid-based thin-layer cytologic preparations of endometrial cancers. Int J Gynecol Cancer. 15:70–80. 2005. View Article : Google Scholar
27	Kawaguchi M, Banno K, Susumu N, et al: Successful analysis of anticancer drug sensitivity by CD-DST using pleural fluid and ascites from patients with advanced ovarian cancer: case reports. Anticancer Res. 25:3547–3551. 2005.PubMed/NCBI
28	Kawamura M, Gika M, Abiko T, et al: Clinical evaluation of chemosensitivity testing for patients with unresectable non-small cell lung cancer (NSCLC) using collagen gel droplet embedded culture drug sensitivity test (CD-DST). Cancer Chemother Pharmacol. 59:507–513. 2007. View Article : Google Scholar
29	Leppard JB and Champoux JJ: Human DNA topoisomerase I: relaxation, roles, and damage control. Chromosoma. 114:75–85. 2005. View Article : Google Scholar : PubMed/NCBI
30	Covey JM, Jaxel C, Kohn KW and Pommier Y: Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res. 49:5016–5022. 1989.PubMed/NCBI
31	Shao RG, Cao CX, Zhang H, Kohn KW, Wold MS and Pommier Y: Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes. EMBO J. 18:1397–1406. 1999. View Article : Google Scholar : PubMed/NCBI
32	Wan S, Capasso H and Walworth NC: The topoisomerase I poison camptothecin generates a Chk1-dependent DNA damage checkpoint signal in fission yeast. Yeast. 15:821–828. 1999. View Article : Google Scholar
33	Cliby WA, Lewis KA, Lilly KK and Kaufmann SH: S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J Biol Chem. 277:1599–1606. 2002. View Article : Google Scholar : PubMed/NCBI
34	Seiler JA, Conti C, Syed A, Aladjem MI and Pommier Y: The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses. Mol Cell Biol. 27:5806–5818. 2007. View Article : Google Scholar : PubMed/NCBI
35	Koster DA, Palle K, Bot ESM, Bjornsti M-A and Dekker NH: Antitumour drugs impede DNA uncoiling by topoisomerase I. Nature. 448:213–217. 2007. View Article : Google Scholar : PubMed/NCBI
36	Patro BS, Frøhlich R, Bohr VA and Stevnsner T: WRN helicase regulates the ATR-CHK1-induced S-phase checkpoint pathway in response to topoisomerase-I-DNA covalent complexes. J Cell Sci. 124:3967–3979. 2011. View Article : Google Scholar : PubMed/NCBI
37	Christmann M, Tomicic MT, Gestrich C, Roos WP, Bohr VA and Kaina B: WRN protects against topo I but not topo II inhibitors by preventing DNA break formation. DNA Repair. 7:1999–2009. 2008. View Article : Google Scholar : PubMed/NCBI
38	Abraham RT: Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 15:2177–2196. 2001. View Article : Google Scholar : PubMed/NCBI
39	Shiloh Y: ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer. 3:155–168. 2003. View Article : Google Scholar : PubMed/NCBI
40	Versini G, Comet I, Wu M, Hoopes L, Schwob E and Pasero P: The yeast Sgs1 helicase is differentially required for genomic and ribosomal DNA replication. EMBO J. 22:1939–1949. 2003. View Article : Google Scholar : PubMed/NCBI
41	Sugiyama T, Yakushiji M, Noda K, et al: Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology. 58:31–37. 2000. View Article : Google Scholar : PubMed/NCBI
42	McGuire WP, Blessing JA, Moore D, Lentz SS and Photopulos G: Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol. 14:792–795. 1996.PubMed/NCBI
43	Rose PG, Blessing JA, Gershenson DM and McGehee R: Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 17:2676–2680. 1999.
44	Banno K, Yanokura M, Kawaguchi M, et al: Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. Int J Oncol. 31:713–720. 2007.PubMed/NCBI
45	Cervical cancer guideline (Version 1. 2012). NCCN Clinical Practice Guidelines in Oncology.
46	Treatment Guidelines for cervical cancer. Japan Society of Gynecologic Oncology. Kanehara & Co; 2011
47	Benedetti-Panici P, Greggi S, Colombo A, et al: Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol. 20:179–188. 2002. View Article : Google Scholar
48	Chang TC, Lai CH, Hong JH, et al: Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. J Clin Oncol. 18:1740–1747. 2000.